KEY PUBLICATIONS
Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial-Mesenchymal Transition
O’Connell I and Dongre A
Molecular Diagnosis and Therapy (Springer Nature). 2023; doi.org/10.1007/s40291-023-00652-3
In this current opinion we provide insights into using the EMT program as a novel criteria for predicting responsiveness of breast tumors to immune checkpoint blockade therapies.
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.
Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA.
Cancer Res. 2017 Aug 1;77(15):3982-3989. doi: 10.1158/0008-5472.CAN-16-3292. Epub 2017 Apr 20. (Cover Page Article)
In this manuscript we establish novel, pre-clinical, murine models of epithelial and mesenchymal tumors and demonstrate that the EMT program leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance to immune checkpoint blockade therapy
Dongre A, Rashidian M, Eaton NE, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner AM, Spranger S and Weinberg RA.
Cancer Discovery, 2021;11:1286–305 DOI: 10.1158/2159-8290.CD-20-0603
In this manuscript we identify the underlying mechanisms of EMT-mediated immunosuppression and demonstrate that quasi-mesenchymal tumors can be completely sensitized to anti-CTLA4 immune checkpoint blockade therapy by targeting the expression of mesenchymal cancer cell-intrinsic CD73
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer.
Dongre A, Weinberg RA.
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84. doi: 10.1038/s41580-018-0080-4. Review.
In this manuscript we describe new insights into the role of the EMT program during cancer progression
Ferrao P, Dongre A, Jolly MK, Jayachandran A, and Thompson R.
Frontiers in Oncology. 2023; Editorial
Dongre A, Ortiz-Cuaran S and Korkaya H.
Front. Immunol. 2022; 13:940164. doi: 10.3389/fimmu.2022.940164
Dongre A, Weinberg RA.
Cell Research. 2021 https://doi.org/10.1038/s41422-021-00574-x
Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE, Minter LM, Osborne BA.
Front Immunol. 2014 Feb 12;5:54
Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, Ploegh HL.
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16971-16980. doi: 10.1073/pnas.1905005116. Epub 2019 Aug 2.
Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, Grotenbreg GM, Bhan A, Weinberg RA, Ploegh HL.
J Exp Med. 2017 Aug 7;214(8):2243-2255. doi: 10.1084/jem.20161950. Epub 2017 Jun 30.
Castaño Z, San Juan BP, Spiegel A, Pant A, DeCristo MJ, Laszewski T, Ubellacker JM, Janssen SR, Dongre A, Reinhardt F, Henderson A, Del Rio AG,
Gifford AM, Herbert ZT, Hutchinson JN, Weinberg RA, Chaffer CL, McAllister SS.
Nat Cell Biol. 2018 Sep;20(9):1084-1097. doi: 10.1038/s41556-018-0173-5. Epub 2018 Aug 27.
Wang H, Xiang D, Liu B, He A, Randle HJ, Zhang KX, Dongre A, Sachs N, Clark AP, Tao L, Chen Q, Botchkarev VV Jr, Xie Y, Dai N, Clevers H, Li Z, Livingston DM.
Cell. 2019 Jun 27;178(1):135-151.e19. doi: 10.1016/j.cell.2019.06.002.
De Cock JM, Shibue T, Dongre A, Keckesova Z, Reinhardt F, Weinberg RA.
Cancer Res. 2016 Dec 1;76(23):6778-6784.
Roderick JE, Gonzalez-Perez G, Kuksin CA, Dongre A, Roberts ER, Srinivasan J, Andrzejewski C Jr, Fauq AH, Golde TE, Miele L, Minter LM.
J Exp Med. 2013 Jul 1;210(7):1311-29.
For a complete list of publications go HERE